We developed a general model for estimating and comparing disease- and treatment-specific lost paid/unpaid production (due to premature death and reduced ability) and informal care received (due to reduced ability) in Italy, starting from survival, demographic and Health-Related Quality of Life (HRQoL) data. Assuming the disease is not selecting a systematically different population in terms of mean wage than the general public, age- and gender-specific yearly production values are estimated combining data from the last Italian Time-Use-Survey on time dedicated to paid and unpaid (household, caring and volunteering) activities, with a) the last Italian Wage-Structure-Survey, for paid activities (Human Capital approach), and b) market prices...
Background Through a comprehensive analysis of Italy’s estimates from the Global Burden of Diseases,...
Background: After 2008 global economic crisis, Italian governments progressively reduced public heal...
Objectives: To investigate how indirect costs are evaluated in pharmacoeconomic studies in Italy and...
We developed a general model for estimating and comparing disease- and treatment-specific lost paid/...
ABSTRACTObjectiveTo estimate a value set for the calculation of Italian-specific quality-adjusted li...
Background: Amenable mortality is an indicator that measures the extent to which health services con...
The most important societal challenge is aging, often associated with chronic disease and increased ...
Italy is characterized by a population aging produced by both life expectancy increases and fertili...
Introduction. In the last decades the demographics of most Western countries have undergone a deep t...
National healthcare systems are increasingly strained by expanding demands of services, whilst growt...
This study aims to develop and validate a prediction model of societal costs during a period of 6-mo...
AIMS AND BACKGROUND: To provide model-based estimates of all cancers patient survival in Italy and i...
AIMS AND BACKGROUND: To provide model-based estimates of all cancers patient survival in Italy and i...
This book examines economic transfers across generations and genders from a European perspective. It...
The Italian health insurance market is currently undersized. The paucity of assured data and the dis...
Background Through a comprehensive analysis of Italy’s estimates from the Global Burden of Diseases,...
Background: After 2008 global economic crisis, Italian governments progressively reduced public heal...
Objectives: To investigate how indirect costs are evaluated in pharmacoeconomic studies in Italy and...
We developed a general model for estimating and comparing disease- and treatment-specific lost paid/...
ABSTRACTObjectiveTo estimate a value set for the calculation of Italian-specific quality-adjusted li...
Background: Amenable mortality is an indicator that measures the extent to which health services con...
The most important societal challenge is aging, often associated with chronic disease and increased ...
Italy is characterized by a population aging produced by both life expectancy increases and fertili...
Introduction. In the last decades the demographics of most Western countries have undergone a deep t...
National healthcare systems are increasingly strained by expanding demands of services, whilst growt...
This study aims to develop and validate a prediction model of societal costs during a period of 6-mo...
AIMS AND BACKGROUND: To provide model-based estimates of all cancers patient survival in Italy and i...
AIMS AND BACKGROUND: To provide model-based estimates of all cancers patient survival in Italy and i...
This book examines economic transfers across generations and genders from a European perspective. It...
The Italian health insurance market is currently undersized. The paucity of assured data and the dis...
Background Through a comprehensive analysis of Italy’s estimates from the Global Burden of Diseases,...
Background: After 2008 global economic crisis, Italian governments progressively reduced public heal...
Objectives: To investigate how indirect costs are evaluated in pharmacoeconomic studies in Italy and...